Bringing bone to the right places

August 16, 2000

New approach to treating osteoporosis uses bone-seeking molecules

Osteoporosis researchers have long dreamed of strengthening bones, but haven't had a method that could stimulate bone growth to the areas that needed it. Now, Canadian researchers may have found such a vehicle, reports the August/September edition of Biotechnology Progress, a peer-reviewed journal of the American Chemical Society, the world's largest scientific society.

The researchers tied small bone-seeking molecules to large proteins capable of stimulating bone growth. The report - from animal testing - is the first successful clinical attempt at steering the proteins to bone, where they can accumulate in the desired areas and help build bone mass. Proteins do not normally go to bone and are cleared from the circulatory system unless they have something to cling to.

Additional research is needed to determine if the accumulated proteins can grow bone tissue, said lead researcher Hasan Uludag, Ph.D., of the University of Alberta in Canada. Translating the animal studies into human trials could take years, he noted. Still, the finding could ultimately lead to a new approach to treating bone disease.

"Therapeutic agents capable of stimulating new bone formation form the basis of a new class of drugs that will not only slow the bone loss, but also will have the potential to restore lost bone mass," Uludag said.

Other researchers have produced bone-aiding proteins, but have not succeeded in attaching them where they might help patients. Current treatments - like estrogen and calcitonin - aim to stem the loss of bone mass rather than rebuild the bone.

Proteins generally known as "growth factors" stimulate certain types of cells necessary for bone growth. The growth factors, the researchers hope, can help re-grow lost bone mass to the areas that need it. As we age, however, the number of such cells decreases. For that reason, it remains to be seen whether the growth factors are effective in an elderly population, Uludag said. If so, they might one day be injected in people who suffer from osteoporosis to stimulate the formation of new bone, he suggested.

"We are trying to 'engineer' the linkages that will target the growth factors to the bones," Uludag said. "If we can put together the proteins that stimulate bone growth with the molecules that go to the bone, we'll have an agent that could work."

Osteoporosis, a degenerative condition usually found in older people, is characterized by low bone mass and bone deterioration. People with osteoporosis have fragile bones that fracture easily. Approximately 10 million people in the United States suffer from the disease, and another 18 million have low bone mass, placing them at an increased risk of developing it, according to the National Osteoporosis Foundation.

Eighty percent of those who suffer from osteoporosis are women, according to foundation statistics.
-end-
The research was funded by the Medical Research Council of Canada.

The online version of the research paper cited above was initially published July 26 on the journal's Web site. Journalists can arrange access to this site by sending an email to tonewsroom@acs.org or calling the contact person for this release.

Dr. Hasan Uludag, Ph.D., is an assistant professor in the department of biomedical engineering at the University of Alberta in Edmonton, Alberta, Canada.

A nonprofit organization with a membership of 161,000 chemists and chemical engineers, the American Chemical Society publishes scientific journals and databases, convenes major research conferences, and provides educational, science policy and career programs in chemistry. Its main offices are in Washington, D.C., and Columbus, Ohio.

American Chemical Society

Related Osteoporosis Articles from Brightsurf:

New opportunities for detecting osteoporosis
Osteoporosis can be detected through low dose computed tomography (LDCT) imaging tests performed for lung cancer screening or other purposes.

Oxytocin can help prevent osteoporosis
In a laboratory experiment with rats, Brazilian researchers succeeded in reversing natural processes associated with aging that lead to loss of bone density and strength.

New strategy against osteoporosis
An international research team has found a new approach that may be able to reduce bone loss in osteoporosis and maintain bone health.

New review on management of osteoporosis in premenopausal women
An IOF and ECTS Working Group have published an updated review of literature published after 2017 on premenopausal osteoporosis.

Cardiac CT can double as osteoporosis test
Cardiac CT exams performed to assess heart health also provide an effective way to screen for osteoporosis, potentially speeding treatment to the previously undiagnosed, according to a new study.

Osteoporosis treatment may also protect against pneumonia
A recent study published in the Journal of Bone and Mineral Research found that nitrogen-containing bisphosphonates (N-BPs) such as alendronate, which are widely used to treat postmenopausal osteoporosis, are linked with lower risks of pneumonia and of dying from pneumonia.

New pharmaceutical target reverses osteoporosis in mice
Biomedical engineers at Duke University have discovered that an adenosine receptor called A2B can be pharmaceutically activated to reverse bone degradation caused by osteoporosis in mouse models of the disease.

A link between mitochondrial damage and osteoporosis
In healthy people, a tightly controlled process balances out the activity of osteoblasts, which build bone, and osteoclasts, which break it down.

Many stroke patients not screened for osteoporosis, despite known risks
Many stroke survivors have an increased risk of osteoporosis, falls or breaks when compared to healthy people.

Many postmenopausal women do not receive treatment for osteoporosis
The benefits of treating osteoporosis in postmenopausal women outweigh the perceived risks, according to a Clinical Practice Guideline issued today by the Endocrine Society.

Read More: Osteoporosis News and Osteoporosis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.